A PHD inhibitor prevents changes in the phosphoproteome and capillary rarefaction by CsA: treatment option for CKD?
Journal
Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
23
05
2022
revised:
08
06
2022
accepted:
10
06
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
28
9
2022
Statut:
ppublish
Résumé
Labes et al. analyze the phosphoproteome in a mouse model of chronic cyclosporine A nephrotoxicity and detect significant changes in the angiogenic pathway. Furthermore, they observe reduced hemoglobin levels and capillary rarefaction in the kidney. The authors show that coadministration of the hypoxia-inducible factor prolyl hydroxylase inhibitor daprodustat almost completely prevents changes of the phosphoproteome and capillary rarefaction, suggesting that prolyl hydroxylase domain enzyme inhibitors may preserve microvasculature of the kidney, which is commonly impaired in chronic kidney disease.
Identifiants
pubmed: 36150758
pii: S0085-2538(22)00532-4
doi: 10.1016/j.kint.2022.06.020
pii:
doi:
Substances chimiques
Hemoglobins
0
Prolyl-Hydroxylase Inhibitors
0
Cyclosporine
83HN0GTJ6D
Prolyl Hydroxylases
EC 1.14.11.-
Hypoxia-Inducible Factor-Proline Dioxygenases
EC 1.14.11.29
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
686-688Commentaires et corrections
Type : CommentOn
Informations de copyright
Copyright © 2022 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.